Free Trial

Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
Achaogen, Inc. stock logo
AKAOQ
Achaogen
$0.03
+0.8%
$0.02
$0.00
$0.05
$1.21M-0.81186,196 shs68,500 shs
Anthera Pharmaceuticals, Inc. stock logo
ANTH
Anthera Pharmaceuticals
$0.00
$0.00
$0.00
N/A1.82208 shsN/A
AOLS
Aeolus Pharmaceuticals
$0.00
$0.00
$0.01
N/A1.2835 shsN/A
Capstone Therapeutics Corp. stock logo
CAPS
Capstone Therapeutics
$1.61
+12.6%
$1.79
$1.30
$16.18
$250K-0.8283,531 shs107,566 shs
NSPX
Inspyr Therapeutics
$0.00
$0.00
$0.07
$1.47M-17.3313.19 million shs29.64 million shs
Investing Strategies To Help Grow Your Retirement Income Cover

Need to stretch out your 401K or Roth IRA plan? Use these time-tested investing strategies to grow the monthly retirement income that your stock portfolio generates.

Get This Free Report

Compare Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
Achaogen, Inc. stock logo
AKAOQ
Achaogen
0.00%0.00%0.00%0.00%0.00%
Anthera Pharmaceuticals, Inc. stock logo
ANTH
Anthera Pharmaceuticals
0.00%0.00%0.00%0.00%0.00%
AOLS
Aeolus Pharmaceuticals
0.00%0.00%0.00%0.00%0.00%
Capstone Therapeutics Corp. stock logo
CAPS
Capstone Therapeutics
+12.59%+6.62%-16.15%-32.35%+160,999,900.00%
NSPX
Inspyr Therapeutics
0.00%0.00%0.00%0.00%0.00%
CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & Valuation
Achaogen, Inc. stock logo
AKAOQ
Achaogen
N/AN/AN/AN/AN/AN/AN/AN/A
Anthera Pharmaceuticals, Inc. stock logo
ANTH
Anthera Pharmaceuticals
N/AN/AN/AN/AN/AN/AN/AN/A
AOLS
Aeolus Pharmaceuticals
N/AN/AN/AN/AN/AN/AN/AN/A
Capstone Therapeutics Corp. stock logo
CAPS
Capstone Therapeutics
N/AN/AN/AN/AN/AN/AN/AN/A
NSPX
Inspyr Therapeutics
N/AN/AN/AN/AN/AN/AN/AN/A
CompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current Price
Achaogen, Inc. stock logo
AKAOQ
Achaogen
0.00
N/AN/AN/A
Anthera Pharmaceuticals, Inc. stock logo
ANTH
Anthera Pharmaceuticals
0.00
N/AN/AN/A
AOLS
Aeolus Pharmaceuticals
0.00
N/AN/AN/A
Capstone Therapeutics Corp. stock logo
CAPS
Capstone Therapeutics
0.00
N/AN/AN/A
NSPX
Inspyr Therapeutics
0.00
N/AN/AN/A
CompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/Book
Achaogen, Inc. stock logo
AKAOQ
Achaogen
$8.73M0.14N/AN/AN/A
Anthera Pharmaceuticals, Inc. stock logo
ANTH
Anthera Pharmaceuticals
N/AN/AN/AN/AN/AN/A
AOLS
Aeolus Pharmaceuticals
N/AN/AN/AN/AN/AN/A
Capstone Therapeutics Corp. stock logo
CAPS
Capstone Therapeutics
$44.88M0.01N/AN/A($19.40) per share-0.08
NSPX
Inspyr Therapeutics
N/AN/AN/AN/A($0.07) per shareN/A
CompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings Date
Achaogen, Inc. stock logo
AKAOQ
Achaogen
-$186.51MN/A0.00N/AN/AN/AN/AN/A
Anthera Pharmaceuticals, Inc. stock logo
ANTH
Anthera Pharmaceuticals
N/AN/A0.00N/AN/AN/AN/AN/AN/A
AOLS
Aeolus Pharmaceuticals
N/AN/A0.00N/AN/AN/AN/AN/AN/A
Capstone Therapeutics Corp. stock logo
CAPS
Capstone Therapeutics
-$2.56MN/A0.00N/AN/AN/AN/AN/A
NSPX
Inspyr Therapeutics
-$6.30MN/A0.00N/AN/AN/AN/A-1,354.49%N/A
CompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive Growth
Achaogen, Inc. stock logo
AKAOQ
Achaogen
N/AN/AN/AN/AN/A
Anthera Pharmaceuticals, Inc. stock logo
ANTH
Anthera Pharmaceuticals
N/AN/AN/AN/AN/A
AOLS
Aeolus Pharmaceuticals
N/AN/AN/AN/AN/A
Capstone Therapeutics Corp. stock logo
CAPS
Capstone Therapeutics
N/AN/AN/AN/AN/A
NSPX
Inspyr Therapeutics
N/AN/AN/AN/AN/A
CompanyDebt-to-Equity RatioCurrent RatioQuick Ratio
Achaogen, Inc. stock logo
AKAOQ
Achaogen
N/AN/AN/A
Anthera Pharmaceuticals, Inc. stock logo
ANTH
Anthera Pharmaceuticals
N/AN/AN/A
AOLS
Aeolus Pharmaceuticals
N/AN/AN/A
Capstone Therapeutics Corp. stock logo
CAPS
Capstone Therapeutics
0.28
1.14
0.47
NSPX
Inspyr Therapeutics
N/A
0.09
0.09
CompanyEmployeesShares OutstandingFree FloatOptionable
Achaogen, Inc. stock logo
AKAOQ
Achaogen
4248.21 millionN/ANot Optionable
Anthera Pharmaceuticals, Inc. stock logo
ANTH
Anthera Pharmaceuticals
20N/AN/ANot Optionable
AOLS
Aeolus Pharmaceuticals
4N/AN/ANot Optionable
Capstone Therapeutics Corp. stock logo
CAPS
Capstone Therapeutics
38160,00090,000N/A
NSPX
Inspyr Therapeutics
1543.15 millionN/ANot Optionable

New MarketBeat Followers Over Time

Media Sentiment Over Time

Achaogen stock logo

Achaogen OTCMKTS:AKAOQ

$0.03 +0.00 (+0.81%)
As of 06/18/2021

Achaogen, Inc., a biopharmaceutical company, focuses on the development and commercialization of antibacterial agents for multi-drug resistant (MDR) gram-negative infections in the United States. The company is principally developing plazomicin for the treatment of serious bacterial infections due to MDR enterobacteriaceae comprising carbapenem-resistant enterobacteriaceae. It is also involved in the development of antibacterial candidate C-Scape, an orally-administered combination of clavulanate and ceftibuten, which targets serious bacterial infections due to expanded spectrum beta-lactamases producing enterobacteriaceae. The company has license and collaboration agreements with Thermo Fisher Scientific, Inc. to develop and commercialize an assay to support plazomicin; Crystal Biosciences, Inc. to discover monoclonal antibodies against multiple targets; Ionis Pharmaceuticals, Inc. for certain patents relating to aminoglycoside antibacterial compounds and related know-how to develop and commercialize certain novel aminoglycoside antibacterial compounds; and Hovione Limited manufacture the active pharmaceutical ingredient for plazomicin. The company was incorporated in 2002 and is based in South San Francisco, California. On April 15, 2019, Achaogen, Inc. filed a voluntary petition for reorganization under Chapter 11 in the U.S. Bankruptcy Court for the District of Delaware. The plan was later approved as Chapter 11 liquidation on May 29, 2020.

Anthera Pharmaceuticals stock logo

Anthera Pharmaceuticals OTCMKTS:ANTH

Anthera Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the development and commercialization of medicines for patients with unmet medical needs. It develops Sollpura, a non-porcine investigational pancreatic enzyme replacement therapy that is in Phase III clinical trial for the treatment of patients with exocrine pancreatic insufficiency; and Blisibimod, which is in Phase II clinical trial for the treatment of B-cell mediated autoimmune diseases, including immunoglobulin A nephropathy or IgA nephropathy. The company has license agreements with Amgen, Inc., and Eli Lilly and Company. Anthera Pharmaceuticals, Inc. was founded in 2004 and is based in Houston, Texas.

Aeolus Pharmaceuticals OTCMKTS:AOLS

Aeolus Pharmaceuticals, Inc., a biopharmaceutical company, develops a platform of novel compounds for use in biodefense, fibrosis, oncology, infectious, and central nervous system diseases in the United States. The company develops a class of catalytic antioxidant compounds as medical countermeasures against nuclear, radiological, and chemical weapons, as well as for diseases and disorders of the respiratory system, central nervous system, and oncology. Its lead compound includes AEOL 10150 that has completed two Phase I clinical trials, which is developed against the pulmonary sub-syndrome of acute radiation syndrome; and for use as a medical countermeasure for exposure to chemical vesicants and nerve agents. The company is also developing AEOL 11114B, AEOL 11203, and AEOL 11207 for the treatment of Parkinson's disease, as well as AEOL 20415 for treating infectious diseases. Aeolus Pharmaceuticals, Inc. was founded in 1994 and is based in Mission Viejo, California.

Capstone Therapeutics stock logo

Capstone Therapeutics NASDAQ:CAPS

$1.61 +0.18 (+12.59%)
As of 07/11/2025 03:59 PM Eastern

Capstone Therapeutics Corp., a biotechnology company, develops novel peptides and other molecules for helping patients with under-served medical conditions in the United States. It develops Apo E mimetic peptide molecule AEM-28 and its analogs that have completed Phase Ia and Phase Ib/IIa clinical trials for lipoprotein metabolism. The company was formerly known as OrthoLogic Corp. and changed its name to Capstone Therapeutics Corp. in May 2010. Capstone Therapeutics Corp. was founded in 1987 and is headquartered in Tempe, Arizona.

Inspyr Therapeutics OTCMKTS:NSPX

Inspyr Therapeutics, Inc. is a pharmaceutical company, which engages in the research and development of novel therapeutics for the treatment of cancer. Its product pipeline includes Mipsagargin, a dual A2A/A2B antagonist, an A2A antagonist, an A2B antagonist, and an A2A agonist. The company was founded by Craig A. Dionne, John T. Issacs, and Samuel R. Denmeade on November 21, 2003 and is headquartered in Westlake Village, CA.